re your comment:>Who are the researchers at the FDA who are going to approve this? Those >same incompetent ones. Whoops.That's exactly why the drug has taken so long to approve, and yes it's certainly an impediment to getting the drug approved, a reason not to buy HEB. But it's also a testament to the power of Ampligen that it's once again knocking at the FDA's door. Political roadblocks have hindered the status of Ampligen from the start, and a few still remain, but somehow the drug is still around. The initial FDA concerns (that the drug was too risky and had too many side-effects) were obviously unfounded, because now the drug is closer to approval than ever, as they're accepting an NDA for review.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra